Anti-Inflammatory Action of Sitagliptin and Linagliptin in Doxorubicin Nephropathy
Background/Aims: Dipeptidyl peptidase-4 (DPP4) inhibitors are known to have a protective effect on diabetic kidney disease, possibly via reduction of oxidative stress and inflammation in the kidney. However, whether these potential mechanisms play a role in non-diabetic proteinuric kidney diseases i...
Main Authors: | Chor Ho Jo, Sua Kim, Joon-Sung Park, Gheun-Ho Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2018-06-01
|
Series: | Kidney & Blood Pressure Research |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/490688 |
Similar Items
-
The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates Endothelial Inflammation and Microvascular Thrombosis in a Sepsis Mouse Model
by: Shen-Chih Wang, et al.
Published: (2022-03-01) -
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
by: Green J, et al.
Published: (2010-10-01) -
Comparative effects of incretin-based therapy on doxorubicin-induced nephrotoxicity in rats: the role of SIRT1/Nrf2/NF-κB/TNF-α signaling pathways
by: Sandy R. Botros, et al.
Published: (2024-02-01) -
Effects of metformin+sitagliptin versus metformin + glibenclamide combinations on lipid profile, body mass index and kidney function in Iraqi patients with type 2 diabetes mellitus.
by: Hassan Mohammed Abbas Al-Temimi, et al.
Published: (2013-06-01) -
Post-marketing Study of Linagliptin: A Pilot Study
by: Gabrielle Kéfrem Alves Gomes, et al.
Published: (2019-05-01)